NCT07672769 Azacitidine High Risk Myelodysplastic Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Turn a newly registered trial into a decision-ready landscape. This focused report examines NCT07672769—Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes (BEXERA)—using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, Drug & Asset MCP for mechanism and development context, and Company & Deal Intelligence MCP for sponsor background. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 20 July 2026; publication date: 20 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why NCT07672769 is a hot trial to watch

High Risk Myelodysplastic Syndrome is increasingly segmented by mechanism, biomarker, treatment setting, geography and endpoint architecture. NCT07672769 is notable because it evaluates Azacitidine in a Phase 2 design while Dose-selection utility score at the end of the primary dose-selection assessment window (3 months from last participant enrollment), calculated per dose using a pre-specified algorithm that integrates: * Efficacy component (achievement of CR + CReq per IWG2023 criteria). * Safety/tolerability component (rate of treatment-related Grade 3-5 treatment-related adverse events \[TRAEs\]). For each arm, there will be an observed efficacy rate (PE) and toxicity rate (PT) and the utility score will be defined as U = PE - ωPT where the ω is a pre-specified weight. serves as the main decision variable. The critical question is whether the protocol can convert its rationale into a clinically interpretable and operationally credible readout.

PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add development-status, target and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The phase label is only the starting point. Allocation is Randomized, masking is Quadruple, and the intervention model is Parallel Assignment. Planned enrollment of 90 participants across Not reported shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.

• Primary: Dose-selection utility score at the end of the primary dose-selection assessment window (3 months from last participant enrollment), calculated per dose using a pre-specified algorithm that integrates: * Efficacy component (achievement of CR + CReq per IWG2023 criteria). * Safety/tolerability component (rate of treatment-related Grade 3-5 treatment-related adverse events \[TRAEs\]). For each arm, there will be an observed efficacy rate (PE) and toxicity rate (PT) and the utility score will be defined as U = PE - ωPT where the ω is a pre-specified weight. (3 months from last participant enrollment)
• Secondary: Proportion of responses meeting CR or CReq based on IWG 2023 criteria. Endpoints of best response 3-months on treatment, 6-months on treatments and through full treatment period. (36 months from enrollment)
• Secondary: cCR as defined by the IWG2023 at any point through participant treatment (36 months from enrollment)
• Secondary: ORR as defined by IWG2006 response criteria and IWG2023 criteria (36 months from enrollment)
• Secondary: OS is defined as the number of months measured from the date of enrollment to the date of death from any cause. (36 months from enrollment)

Benchmark readouts in the surrounding field

• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of RDX-002 on Postprandial Triglycerides in Patients Discontinuing the Glucagon-like Peptide-1 (GLP-1) Agonists, Semaglutide, or Tirzepatide for the Treatment of Obesity (Phase 2): Incremental Postprandial Triglycerides (TG)(Mean) = 43.81 percent change (Standard Deviation, 92.373); Incremental Postprandial Triglycerides (TG)(Mean) = -51.91 percent change (Standard Deviation, 72.293)
• A Phase II Study to Evaluate the Delay in Ovulation Following Oral Levonorgestrel Plus Meloxicam Compared to Placebo in Obese But Normal Menstruating Women (Phase 2): Interval From First Dose to Evidence of Ovulation.(Mean) = 2.67 Number of days (Standard Deviation, 1.53); Interval From First Dose to Evidence of Ovulation.(Mean) = 4.0 Number of days (Standard Deviation, 0)
• A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight (Phase 2): Percent Change From Baseline in Body Weight at Week 48(Least Squares Mean) = -0.4 percent change (Standard Error, 0.91); Percent Change From Baseline in Body Weight at Week 48(Least Squares Mean) = -9.4 percent change (Standard Error, 1.60)

These indexed results are contextual benchmarks, not direct head-to-head evidence. Population, treatment line, endpoint definitions, follow-up and analysis sets may differ. Their value is to clarify the type and magnitude of evidence already visible in the competitive landscape.

Build a living trial monitor: connect to PatSnap MCP Servers and track status changes, endpoint revisions, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: Azacitidine (Approved; DNMT1); Bexmarilimab (Phase 2; STAB1)

Company & Deal Intelligence context: Faron Pharmaceuticals Oy — Finland — https://www.faron.com

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
• Sequencing evidence: comparative data after the most relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter probability of success before a headline data release.

Bottom line

NCT07672769 is a focused lens on High Risk Myelodysplastic Syndrome development. Its value will be determined by whether Azacitidine can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from indexed benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.